ASX 200 morning report – CSL, MTS & PDL shares in focus
Drew Meredith, CFP
March 17, 2021
The ASX 200 (ASX:XJO) is set to fall when the
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The ASX 200 (ASX:XJO) is set to fall when the
The ASX 200 (ASX:XJO) is expected to rise when the
The recent correction in the tech sector might present some
According to new research, the ASX has been the best
The CSL Limited (ASX:CSL) share price fell another 4% yesterday,
The ASX 200 (ASX:XJO) is heading towards another negative open
The S&P/ASX 200 (INDEXASX:XJO) finished flat on Thursday, but with
The CSL Limited (ASX:CSL) share price has risen after the
I think it’s a pretty difficult investing environment right now,
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
